Related Experiment Video
Updated: Jun 15, 2025
Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
Published on: April 18, 2025
Advances on cancer vaccine trials registered in China and the USA in 2014-2024
Wei Shi1,2,3,4, Zhuo Chen1,2,3,4, Qin Yu1,2,3,4
1National Drug Clinical Trial Institution of West China Second Hospital, Sichuan University, Chengdu, China.
Objective:
The clinical trials of cancer vaccine in China and the USA were summarized and compared over the past decade, thus putting forward suggestions for future clinical development in this field.
Methods:
Mainly based on the Centre for Drug Evaluation of China National Medical Products Administration website (NMPA) and ClinicalTrials.gov, a list and detailed information of cancer vaccine trials in China and the USA were acquired, respectively. Vaccines licensed for use in China and the USA were acquired from NMPA and Food and Drug Administration (FDA), respectively. Subgroup comparison in terms of initiated trials was conducted between the two countries.
Results:
In 2014-2024, there were 89 trials and 757 trials of cancer vaccine registered in China and the USA, respectively. In terms of the phase distribution, there were less phase I (28.1% vs 52.1%), phase II (15.7% vs 36.3%), and more phase III (40.5% vs 7.9%), phase IV (15.7% vs 3.7%) trials in China compared with those in the USA (χ2 = 116.58, P < 0.001). Regarding the trial scope, the proportion of global trials was significantly lower in China than that in the USA (2.2% vs 47.6%, χ2 = 66.78, P < 0.001). A significantly higher contribution rate was made by the top 20 pharmaceutical companies in China than that in the USA (16.9% vs 3.0%, χ2 = 35.43, P < 0.001). The numbers of trial status on open, completed and suspended in China are more than those in the USA (56.2%, 41.6%, 1.1% vs 43.6, 29.9%, 0.7%), while terminated trial is less than that in the USA (1.1% vs 9.1%). 5 cancer types were identified in China while there were more than 20 cancer types in the USA. Six cancer vaccines were approved in China while one was approved in the USA. With respect to indications, one cancer type was covered by the approved vaccines in China, which was fewer than the number of cancer types covered by the approved vaccines in the USA.
Conclusion:
Both China and the USA have made great progress in cancer vaccines in 2014-2024. The difference and gap between China and the USA highlight that more efforts should be paid on innovative cancer vaccines in China. Perhaps in the future, we can pay more attention to increasing the investment in drug research and development, carrying out more global multi-center clinical trials and participating more in trials led by top 20 pharmaceutical companies worldwide.
Insights
Cancer vaccine clinical trials in China and the USA show differing phase distributions and global participation. China leads in approved vaccines but covers fewer indications, suggesting a need for increased investment in innovative cancer vaccines and global trials.
Area of Science:
- Oncology
- Vaccinology
- Clinical Research
Background:
- Cancer vaccines represent a significant area of therapeutic development.
- Comparative analysis of clinical trial landscapes between major global players is crucial for strategic advancement.
- Understanding regional differences in cancer vaccine research provides insights into global health priorities.
Purpose of the Study:
- To summarize and compare clinical trials of cancer vaccines in China and the USA over the past decade (2014-2024).
- To identify key differences in trial phases, scope, and outcomes between the two countries.
- To provide recommendations for future clinical development of cancer vaccines.
Main Methods:
- Data on cancer vaccine trials were collected from the China National Medical Products Administration (NMPA) and ClinicalTrials.gov.
- Information on licensed vaccines was obtained from the NMPA and the US Food and Drug Administration (FDA).
- Subgroup comparisons were performed based on trial initiation, phase distribution, scope, and company involvement.
Main Results:
- The USA registered significantly more cancer vaccine trials (757) than China (89) between 2014-2024.
- China's trials showed a higher proportion of Phase III and IV, while the USA had more Phase I and II.
- The USA conducted more global trials, whereas China had a higher contribution rate from its top pharmaceutical companies; China approved six vaccines for one cancer type, while the USA approved one vaccine covering multiple cancer types.
Conclusions:
- Both China and the USA have advanced cancer vaccine research, but significant differences exist.
- China's focus on later-phase trials and fewer indications suggests a need for greater investment in innovative vaccine development and global multi-center trials.
- Increased participation in global trials and collaboration with leading pharmaceutical companies could accelerate cancer vaccine progress in China.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:21Cancer Survival Analysis
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...